We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2),  influenza viruses, noroviruses and hepatitis C viruses.  We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat pandemic and seasonal influenza and the global COVID-19 health crisis. Given the growing global need for an effective, safe antiviral treatment, we are advancing multiple antiviral therapeutic candidates as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.